Navigation Links
Tandem Diabetes Care Reports Second Quarter 2014 Financial Results
Date:7/31/2014

SAN DIEGO, July 31, 2014 /PRNewswire/ -- Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the t:slim® Insulin Pump, today reported its financial results for the quarter ended June 30, 2014.

In comparing the second quarter of 2014 to the same period of 2013:

  • Sales grew 86 percent to $10.3 million from $5.5 million
  • t:slim Pump shipments grew 64 percent to 2,235 pumps from 1,363 pumps
  • In comparing six months ended June 30, 2014 to the same period of 2013:

  • Sales grew 67 percent to $18.3 million from $11.0 million, which included $1.9 million of t:slim Pump sales recognized in the first quarter 2013 that were shipped in the fourth quarter of 2012
  • t:slim Pump shipments grew 79 percent to 3,958 pumps from 2,215 pumps
  • "In addition to seeing continued, increased adoption of the t:slim Pump and meaningful gross margin improvement in the second quarter, we also made significant progress with our new products in development," said Kim Blickenstaff, President and Chief Executive Officer of Tandem Diabetes Care. "We recently submitted a PMA application to the FDA for the t:slim G4™ Insulin Pump, which integrates our t:slim technology with the Dexcom® G4® Platinum CGM System.  This is an important milestone for Tandem as we work to expand our product portfolio to meet the various needs of the diabetes community."

    For the quarter ended June 30, 2014, gross margin was 34 percent compared to 7 percent for the same period of 2013.  The second quarter of 2014 benefited from improvements in the manufacturing process and increased production volumes.  

    For the second quarter of 2014, operating expenses totaled $21.8 million compared to $14.1 million for the same period of 2013.  The increases in operating expenses are primarily associated with the expansion of commercial operations and non-cash, stock-based compensation.

    Operating loss for the second quarter of 2014 was $18.3 million, compared to $13.7 million for the same period of 2013.  This included non-cash, stock-based compensation of $3.5 million for the quarter ended June 30, 2014 compared to $0.5 million for the comparable period of 2013.

    As of June 30, 2014, the Company had $96.3 million in cash, cash equivalents and short-term investments.

    For the year ending December 31, 2014, the Company's guidance is as follows:

  • sales are estimated to be in the range of $48.0 million to $54.0 million, and
  • operating margin is estimated to be in the range of negative 130 percent to 140 percent, which includes approximately $15.0 million to $16.0 million in non-cash, stock-based compensation expense.
  • Conference Call
    The Company will hold a conference call and simultaneous webcast today at 4:30pm Eastern Time (1:30pm Pacific Time).  The link to the webcast will be available by accessing the Investor Center of the Tandem Diabetes Care website at http://investor.tandemdiabetes.com, and will be archived for 30 days.  To listen to the conference call via phone, please dial 855-427-4396 (U.S./Canada) or 484-756-4261 (International) and use the participant code "72496087".

    About Tandem Diabetes Care, Inc.
    Tandem Diabetes Care, Inc. (www.tandemdiabetes.com) is a medical device company with an innovative, user-centric and integrated approach to the design, development and commercialization of products for people with insulin-dependent diabetes. The Company manufactures and sells the t:slim Insulin Pump, the slimmest and smallest durable insulin pump currently on the market, and the first and only insulin pump with a high resolution, color touch screen. Tandem is based in San Diego, California.

    t:slim, t:connect and Tandem Diabetes Care are registered trademarks of Tandem Diabetes Care, Inc.

    Dexcom and G4 Platinum are registered trademarks of Dexcom, Inc.

    Follow Tandem Diabetes Care:
    Twitter @tandemdiabetes, use #tslim, #tconnect and $TNDM.
    Facebook at www.facebook.com/TandemDiabetes 
    LinkedIn at www.linkedin.com/in/tandemdiabetes

    Forward Looking Statement
    This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. These forward-looking statements relate to the Company's projected financial results, the Company's ability to further drive adoption of the t:slim® Insulin Pump in the insulin dependent diabetes market, the Company's ability to manage manufacturing costs, the Company's ability to expand its product portfolio and the Company's ability to gain FDA approval and commercially launch the t:slim G4 Insulin Delivery System. The Company's actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties. For instance, successful commercialization of the Company's products may be negatively impacted by lack of market acceptance by physicians and people with diabetes. Other risks and uncertainties include the Company's inability to manufacture products in commercial quantities at an acceptable cost and in accordance with quality requirements; the Company's inability to contract with additional third-party payors for reimbursement of the Company's products; possible delays in the Company's product development programs; possible future actions of the U.S. Food and Drug Administration or any other regulatory body or governmental authority; and other risks identified in the Company's most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q, as well as other documents that the Company files with the Securities and Exchange Commission. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. Tandem undertakes no obligation to update or review any forward-looking statement in this press release because of new information, future events or other factors. 

     TANDEM DIABETES CARE, INC.
    CONDENSED BALANCE SHEETS
    (in thousands)June 30, 2014

    (unaudited)December 31, 2013AssetsCurrent assets:Cash, cash equivalents and short-term investments$
    94,305
    $
    29,480
    Restricted cash2,0002,050Accounts receivable, net4,3625,299Inventory, net11,12110,330Other current assets2,6351,830Total current assets114,423148,989Property and equipment, net12,4769,886Other long term assets3,1183,340Total assets$
    30,017
    $
    2,215
    Liabilities and stockholders' equityCurrent liabilities:Accounts payable, accrued expense and employee-related liabilities 

    $
    9,705
    $
    ,102
    Deferred revenue514411Other current liabilities2,9924,086Total current liabilities13,21114,599Notes payable—long-term29,39229,397Other long-term liabilities3,8672,682Total stockholders' equity83,547115,537Total liabilities and stockholders' equity$
    30,017
    $
    2,215
     

     

     TANDEM DIABETES CARE, INC.
    CONDENSED STATEMENTS OF OPERATIONS
    (unaudited)
    (in thousands – except per share data)Three Months Ended
     June 30,Six Months Ended
    June 30,2014201320142013Sales$   10,255$   5,528$   18,320$10,986Cost of sales6,8065,12214,0058,540Gross profit3,4494064,3152,446Operating expenses:Selling, general and administrative18,06911,32436,10918,208Research and development3,6982,7597,3625,081Total operating expenses21,76714,08343,47123,289Operating loss(18,318)(13,677)(39,156)(20,843)Other expense, netOther expense, net(879)(1,171)(2,003)(2,337)Change in fair value of stock warrants-(453)-(3,284)Total other expense, net(879)(1,624)(2,003)(5,621)Net loss$ (19,197)$ (15,301)$ (41,159)$ (26,464)Net loss per share, basic and diluted$
    (0.83)
    $  (72.50)$
    (1.79)
    $   (75.42)Weighted average shares used to compute basic and diluted net loss per share 

    23,098 

    211 

    23,017 

    351 

    Logo - http://photos.prnewswire.com/prnh/20131220/LA37333LOGO


    '/>"/>
    SOURCE Tandem Diabetes Care, Inc.
    Copyright©2014 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Tandem Diabetes Care Acquires Select Patents and Patent Applications from Smiths Medical
    2. Data Related to Chimerixs Antiviral CMX001 to be Presented in Three Poster Sessions at the BMT Tandem Meetings
    3. Data Demonstrating the Safety and Efficacy of Chimerixs Antiviral CMX001 Presented at BMT Tandem Meetings
    4. Tandem Diabetes Care Names Lonnie Smith As Chairman Of The Board
    5. Tandem Diabetes Care Announces FDA Clearance of t:connect Diabetes Management Application for Use with t:slim Insulin Pump
    6. TANDEM DIABETES CARE BECOMES PRESENTING SPONSOR OF THE GREATEST AWARDS SHOW IN DIABETES
    7. Tandem Diabetes Care Prices Initial Public Offering
    8. Tandem Diabetes Care Announces Exercise of Option to Purchase Additional Shares in Initial Public Offering of Common Stock
    9. Tandem Diabetes Care Announces Closing of Initial Public Offering
    10. Tandem Diabetes Care Initiates Voluntary Recall for Specific Lots of Insulin Cartridges Used with t:slim Insulin Pump
    11. Global NewBorn Screening (Tandem Mass Spectrometry, Immunoassay, Enzyme Assay, Electrophoresis, Pulse Oximeter) Market - Forecast to 2019
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:2/12/2016)... 2016  OMS Supply, a large provider of oral ... today the recent launching of their new company website. ... features that enhance the user experience and enable practitioners ... --> --> Despite the ... that started in early 2016, they have already made ...
    (Date:2/11/2016)... -- - Cardiac Marker Diagnostic Testing ... Cancer Therapy. - European Point of Care Diagnostic ... - Key Diagnostic Testing Markets. - Molecular Diagnostics ... Testing. - Molecular Diagnostics in Infectious Disease Testing. ... Products World Markets. - Point of Care Diagnostic ...
    (Date:2/11/2016)... 11, 2016  Kindred Biosciences, Inc. (NASDAQ: KIN ... the lives of pets, today announced the submission to ... Animal Drug Application (NADA) for Zimeta™ (dipyrone injection, KIND-012).  ... of Zimeta for the control of pyrexia (fever) in ... --> --> The Chemistry, Manufacturing, ...
    Breaking Medicine Technology:
    (Date:2/13/2016)... ... February 13, 2016 , ... Good news ... first in the area to offer AngioPlex™ Optical Coherence Tomography (OCT) Angiography, imaging ... as macular degeneration, diabetic retinopathy, and other vascular conditions. , In just a ...
    (Date:2/13/2016)... ... February 13, 2016 , ... Many individuals looking to lead a ... multitude of reasons. IsoPasta by Isolator Fitness has delved into this niche allowing ... without the high-carb repercussions. IsoPasta has 30 grams of protein and only 7 ...
    (Date:2/13/2016)... ... February 13, 2016 , ... Christie Medical ... in-kind gift of a VeinViewer® Vision vein finder for the nursing ... start an IV and draw blood, combining technology with traditional technique. , “VeinViewer ...
    (Date:2/12/2016)... ... 2016 , ... According to an article published February 4th on ... portion of hernia repairs throughout the United States. Commenting on this article, Beverly Hills ... this trend has not only been expected, but it seems to be a natural ...
    (Date:2/12/2016)... Raton, FL (PRWEB) , ... February 12, 2016 ... ... largest non-profit organization devoted exclusively to funding innovative lymphoma research and serving the ... services – hosted over 250 members of South Florida’s philanthropic community at its ...
    Breaking Medicine News(10 mins):